CN114262327B - 一种her2小分子抑制剂图卡替尼的制备工艺 - Google Patents
一种her2小分子抑制剂图卡替尼的制备工艺 Download PDFInfo
- Publication number
- CN114262327B CN114262327B CN202111652855.9A CN202111652855A CN114262327B CN 114262327 B CN114262327 B CN 114262327B CN 202111652855 A CN202111652855 A CN 202111652855A CN 114262327 B CN114262327 B CN 114262327B
- Authority
- CN
- China
- Prior art keywords
- formula
- compound represented
- reaction
- compound
- stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 150000003384 small molecules Chemical class 0.000 title abstract description 7
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title abstract description 6
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title abstract description 6
- 239000003112 inhibitor Substances 0.000 title abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 264
- 238000006243 chemical reaction Methods 0.000 claims abstract description 89
- 238000000034 method Methods 0.000 claims abstract description 47
- 238000010438 heat treatment Methods 0.000 claims abstract description 32
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 claims abstract description 25
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 claims abstract description 25
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 78
- 238000003756 stirring Methods 0.000 claims description 64
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 54
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 48
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 39
- 239000012046 mixed solvent Substances 0.000 claims description 26
- 239000003208 petroleum Substances 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 20
- 239000000741 silica gel Substances 0.000 claims description 20
- 229910002027 silica gel Inorganic materials 0.000 claims description 20
- 239000012295 chemical reaction liquid Substances 0.000 claims description 18
- 239000012156 elution solvent Substances 0.000 claims description 18
- 239000011259 mixed solution Substances 0.000 claims description 18
- 238000000746 purification Methods 0.000 claims description 17
- 239000012267 brine Substances 0.000 claims description 15
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 14
- 239000012044 organic layer Substances 0.000 claims description 12
- 230000035484 reaction time Effects 0.000 claims description 11
- 238000005406 washing Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 238000004537 pulping Methods 0.000 claims description 7
- 238000004809 thin layer chromatography Methods 0.000 claims description 7
- 239000012074 organic phase Substances 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- 239000012043 crude product Substances 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000003480 eluent Substances 0.000 claims 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 abstract description 10
- 238000006751 Mitsunobu reaction Methods 0.000 abstract description 7
- 238000005658 halogenation reaction Methods 0.000 abstract description 6
- 230000007547 defect Effects 0.000 abstract description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- SDEAXTCZPQIFQM-UHFFFAOYSA-N 6-n-(4,4-dimethyl-5h-1,3-oxazol-2-yl)-4-n-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine Chemical compound C=1C=C(OC2=CC3=NC=NN3C=C2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2NC1=NC(C)(C)CO1 SDEAXTCZPQIFQM-UHFFFAOYSA-N 0.000 description 8
- 230000036632 reaction speed Effects 0.000 description 8
- 229950003463 tucatinib Drugs 0.000 description 5
- VGUWZCUCNQXGBU-UHFFFAOYSA-N 3-[(4-methylpiperazin-1-yl)methyl]-5-nitro-1h-indole Chemical compound C1CN(C)CCN1CC1=CNC2=CC=C([N+]([O-])=O)C=C12 VGUWZCUCNQXGBU-UHFFFAOYSA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 229940125497 HER2 kinase inhibitor Drugs 0.000 description 1
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- NONOKGVFTBWRLD-UHFFFAOYSA-N isocyanatosulfanylimino(oxo)methane Chemical compound O=C=NSN=C=O NONOKGVFTBWRLD-UHFFFAOYSA-N 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229940124655 tukysa Drugs 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (27)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111652855.9A CN114262327B (zh) | 2021-12-30 | 2021-12-30 | 一种her2小分子抑制剂图卡替尼的制备工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111652855.9A CN114262327B (zh) | 2021-12-30 | 2021-12-30 | 一种her2小分子抑制剂图卡替尼的制备工艺 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114262327A CN114262327A (zh) | 2022-04-01 |
CN114262327B true CN114262327B (zh) | 2023-01-03 |
Family
ID=80831785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111652855.9A Active CN114262327B (zh) | 2021-12-30 | 2021-12-30 | 一种her2小分子抑制剂图卡替尼的制备工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114262327B (zh) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11578074B2 (en) * | 2017-09-01 | 2023-02-14 | Shanghai Pharmaceuticals Holding Cd., Ltd. | Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application |
TWI811358B (zh) * | 2018-05-08 | 2023-08-11 | 大陸商迪哲(江蘇)醫藥股份有限公司 | ErbB受體抑制劑 |
CN112159404B (zh) * | 2020-10-16 | 2022-11-18 | 山东汇海医药化工有限公司 | 一种妥卡替尼的制备方法 |
CN112898298A (zh) * | 2021-01-26 | 2021-06-04 | 上海法默生物科技有限公司 | 一种妥卡替尼中间体的制备方法 |
-
2021
- 2021-12-30 CN CN202111652855.9A patent/CN114262327B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN114262327A (zh) | 2022-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110950872A (zh) | 制备靶向抗癌药avapritinib的方法 | |
CN110938077A (zh) | 合成Avapritinib的方法 | |
CN111362923A (zh) | 制备ret抑制剂普拉塞替尼的方法、以及普拉塞替尼的中间体及其制备方法 | |
CN111440151A (zh) | 制备抗肿瘤药普拉赛替尼的方法 | |
CN114262327B (zh) | 一种her2小分子抑制剂图卡替尼的制备工艺 | |
CN113651798A (zh) | 富马酸伏诺拉生的制备方法 | |
CN107118215B (zh) | 一种治疗乳腺癌药物瑞博西尼中间体的制备方法 | |
CN112625038A (zh) | 制备瑞普替尼的方法 | |
CN112778303A (zh) | Cdk4/6激酶抑制剂shr6390的制备方法 | |
CN114213404B (zh) | Vegfr抑制剂替沃扎尼的合成工艺 | |
CN110922409A (zh) | 制备btk抑制剂泽布替尼的方法 | |
CN114014864B (zh) | 一种曲拉西利化合物的制备工艺 | |
CN111116477A (zh) | 多拉米胺的合成工艺 | |
CN113880844B (zh) | Wee1蛋白激酶抑制剂adavosertib的化学合成方法 | |
CN114369085A (zh) | 盐酸Asciminib的制备方法 | |
CN114230568B (zh) | 一种her2小分子抑制剂图卡替尼的制备方法 | |
CN114853756B (zh) | 化合物Tomivosertib的制备工艺 | |
CN116514684B (zh) | 一种o-磺基-l-酪氨酸钠盐的制备方法 | |
CN114671869B (zh) | 化合物Tomivosertib的合成方法 | |
CN111057075B (zh) | Ret抑制剂及其制备方法 | |
CN113735863A (zh) | Wee1抑制剂adavosertib的制备工艺 | |
CN111662233B (zh) | 一种一步法合成4-氯-1h-咪唑-2-羧酸乙酯的方法 | |
CN114213405A (zh) | Vegfr抑制剂替沃扎尼的制备方法 | |
CN114736205B (zh) | 化合物Tomivosertib的制备方法 | |
CN113105385B (zh) | 一种左布比卡因的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation of Tucatinib, a HER2 small molecule inhibitor Effective date of registration: 20230704 Granted publication date: 20230103 Pledgee: Agricultural Bank of China Co.,Ltd. Wuhan Branch Business Department Pledgor: Wuhan Jiuzhou Yumin Medical Technology Co.,Ltd. Registration number: Y2023420000290 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20230103 Pledgee: Agricultural Bank of China Co.,Ltd. Wuhan Branch Business Department Pledgor: Wuhan Jiuzhou Yumin Medical Technology Co.,Ltd. Registration number: Y2023420000290 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation process of a HER2 small molecule inhibitor Tucatinib Granted publication date: 20230103 Pledgee: Agricultural Bank of China Co.,Ltd. Wuhan Branch Business Department Pledgor: Wuhan Jiuzhou Yumin Medical Technology Co.,Ltd. Registration number: Y2024980025475 |